Nurix Therapeutics Announces Presentations at the 67th American Society of Hematology (ASH) Annual Meeting

Core Insights - Nurix Therapeutics, Inc. announced updated clinical data from the NX-5948-301 Phase 1a/1b clinical trial will be presented at the 67th American Society of Hematology Annual Meeting, focusing on treatments for chronic lymphocytic leukemia (CLL) and Waldenström macroglobulinemia [1][2] Clinical Presentations - An oral presentation titled "Bexobrutideg (NX-5948), a Novel Bruton's Tyrosine Kinase (BTK) Degrader, Demonstrates Rapid and Durable Clinical Responses in Relapsed / Refractory Chronic Lymphocytic Leukemia (CLL)" will take place on December 6, 2025, featuring new findings [3] - A poster presentation will showcase updated results for Waldenström macroglobulinemia, highlighting the clinical activity and safety of Bexobrutideg [4] Mechanistic Insights - Nurix and collaborators will present new insights into resistance mechanisms to BTK-targeted therapies, expanding the understanding of BTK biology [2] Product Information - Bexobrutideg (NX-5948) is an investigational small molecule degrader of BTK, currently evaluated in pivotal and ongoing clinical trials for relapsed or refractory CLL and B cell malignancies [5] Company Overview - Nurix Therapeutics focuses on the discovery and development of targeted protein degradation medicines, aiming to improve treatment options for cancer and autoimmune diseases [6][7]